Oral ketamine as a positive control in human abuse potential studies

Drug and Alcohol Dependence

Volumn 114, Issue 2-3, 2011, Pages 185-193

  Shram, M J ^a   Sellers, E M ^a,b   Romach, M K ^a,b  

^a Kendle Early Stage Toronto   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Abuse potential; Human; Ketamine; Safety; Subjective effects

Indexed keywords

AMPHETAMINE; KETAMINE; PLACEBO; RECREATIONAL DRUG;

ADULT; ARTICLE; CONCENTRATION LOSS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISSOCIATION; DIZZINESS; DRUG ABUSE; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EUPHORIA; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL DISEASE; NORMAL HUMAN; PERCEPTION; PERCEPTION DISORDER; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SENSORY DYSFUNCTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADULT; BEHAVIOR, ADDICTIVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EMOTIONS; FEMALE; HUMANS; KETAMINE; MALE; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 79952703519     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.10.002     Document Type: Article

References (46)

1. Aalto S., Hirvonen J., Kajander J., Scheinin H., Nagren K., Vilkman H., Gustafsson L., Syvalahti E., Hietala J. Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berl.) 2002, 164:401-406.
2. Balster R.L., Bigelow G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 2003, 70:S13-S40.
3. Blonk M.I., Koder B.G., van den Bemt P.M., et al. Use of oral ketamine in chronic pain management: a review. Eur. J. Pain 2010, 14(5):466-472.
4. Bowdle T.A., Radant A.D., Cowley D.S., Kharasch E.D., Strassman R.J., Roy-Byrne P.P. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 1998, 88:82-88.
5. Broadbear J.H., Winger G., Woods J.H. Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys. Psychopharmacology (Berl.) 2004, 176:398-406.
6. Carroll M.E. Tolerance to the behavioral effects of orally self-administered phencyclidine. Drug Alcohol Depend. 1982, 9:213-224.
7. Carroll M.E., Stotz D.C. Oral d-amphetamine and ketamine self-administration by rhesus monkeys: effects of food deprivation. J. Pharmacol. Exp. Ther. 1983, 227:28-34.
8. Clements J.A., Nimmo W.S., Grant I.S. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J. Pharm. Sci. 1982, 71:539-542.
9. Cole J.O., Orzack M.H., Beake B., Bird M., Bar-Tal Y. Assessment of the abuse liability of buspirone in recreational sedative users. J. Clin. Psychiatry 1982, 43:69-75.
10. Cole J.O., Pope H.G., LaBrie R., Ionescu-Pioggia M. Assessing the subjective effects of stimulants in casual users. A methodology and preliminary results. Clin. Pharmacol. Ther. 1978, 24:243-252.
11. Cuddy M.L. Common drugs of abuse-Part II. J. Pract. Nurs. 2004, 54:5-31.
12. Dalgarno P.J., Shewan D. Illicit use of ketamine in Scotland. J. Psychoactive Drugs 1996, 28:191-199.
13. Dillmann J. Ketamine abuse-a new edge. Todays Surg. Nurse. 1998, 20:37-39.
14. Enarson M.C., Hays H., Woodroffe M.A. Clinical experience with oral ketamine. J. Pain Symptom Manage. 1999, 17:384-386.
15. FDA Center for Drug Evaluation and Research Draft Guidance for Industry: Assessment of Abuse Potential of Drugs 2010.
16. Grant I.S., Nimmo W.S., Clements J.A. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br. J. Anaesth. 1981, 53:805-810.
17. Griffiths R.R., Troisi J.R., Silverman K., Mumford G.K. Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav. Pharmacol. 1993, 4:3-13.
18. Hartvig P., Valtysson J., Lindner K.J., Kristensen J., Karlsten R., Gustafsson L.L., Persson J., Svensson J.O., Øye I., Antoni G., Westerberg G., Långström B. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin. Pharmacol. Ther. 1995, 58:165-173.
19. Houtsmuller E.J., Henningfield J.E., Stitzer M.L. Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology (Berl.) 2003, 167:20-27.
20. Jansen K.L. A review of the nonmedical use of ketamine: use, users and consequences. J. Psychoactive Drugs 2000, 32:419-433.
21. Johanson C.E., Uhlenhuth E.H. Drug preference and mood in humans: d-amphetamine. Psychopharmacology (Berl.) 1980, 71:275-279.
22. Johanson C.E., Uhlenhuth E.H. Drug preference and mood in humans: diazepam. Psychopharmacology (Berl.) 1980, 71:269-273.
23. Kannan T.R., Saxena A., Bhatnagar S., Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J. Pain Symptom Manage. 2002, 23:60-65.
24. Kaplan H.L. Representation of on-line questionnaires in an ediable, auditable database. Behav. Res. Models Instrum. Comput. 1992, 24:373-384.
25. Klein M., Calderon S., Hayes B. Abuse liability assessment of neuroprotectants. Ann. N. Y. Acad. Sci. 1999, 890:515-525.
26. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
27. Krystal J.H., Perry E.B., Gueorguieva R., Belger A., Madonick S.H., bi-Dargham A., Cooper T.B., MacDougall L., bi-Saab W., D'Souza D.C. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch. Gen. Psychiatry 2005, 62:985-994.
28. Krystal J.H., Petrakis I.L., Webb E., Cooney N.L., Karper L.P., Namanworth S., Stetson P., Trevisan L.A., Charney D.S. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch. Gen. Psychiatry 1998, 55:354-360.
29. Langsjo J.W., Kaisti K.K., Aalto S., Hinkka S., Aantaa R., Oikonen V., Sipila H., Kurki T., Silvanto M., Scheinin H. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003, 99:614-623.
30. Langsjo J.W., Maksimow A., Salmi E., Kaisti K., Aalto S., Oikonen V., Hinkka S., Aantaa R., Sipila H., Viljanen T., Parkkola R., Scheinin H. S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. Anesthesiology 2005, 103:258-268.
31. Lofwall M.R., Griffiths R.R., Mintzer M.Z. Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults. Exp. Clin. Psychopharmacol. 2006, 14:439-449.
32. Martin W.R., Sloan J.W., Sapira J.D., Jasinski D.R. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 1971, 12:245-258.
33. Mikkelsen S., Jorgensen H., Larsen P.S., Brennum J., Dahl J.B. Effect of oral ketamine on secondary hyperalgesia, thermal and mechanical pain thresholds, and sedation in humans. Reg. Anesth. Pain Med. 2000, 25:452-458.
34. Morgan C.J., Mofeez A., Brandner B., Bromley L., Curran H.V. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 2004, 29:208-218.
35. Muetzelfeldt L., Kamboj S.K., Rees H., Taylor J., Morgan C.J., Curran H.V. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008, 95:219-229.
36. Petrakis I.L., Limoncelli D., Gueorguieva R., Jatlow P., Boutros N.N., Trevisan L., Gelernter J., Krystal J.H. Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am. J. Psychiatry 2004, 161:1776-1782.
37. Rabiner E.A. Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?. J. Psychopharmacol. 2007, 21:253-258.
38. Schmid R.L., Sandler A.N., Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999, 82:111-125.
39. Tancer M.E., Johanson C.E. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend. 2001, 65:97-101.
40. US Department of Justice Drugs and Chemicals of Concern: Ketamine 2004, Drug Enforcement Administration.
41. Vadhan N.P., Hart C.L., Roe B., Colley J., Haney M., Foltin R.W. Substance use and psychosocial outcomes following participation in residential laboratory studies of marijuana, methamphetamine and zolpidem. Am. J. Drug Alcohol Abuse 2006, 32:589-597.
42. van der Kam E.L., De V.J., Tzschentke T.M. Effect of 2-methyl-6-(phenylethynyl) pyridine on intravenous self-administration of ketamine and heroin in the rat. Behav. Pharmacol. 2007, 18:717-724.
43. Wang H., Tompkins L.M. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr. Drug Metab. 2008, 9:598-610.
44. Weiner A.L., Vieira L., McKay C.A., Bayer M.J. Ketamine abusers presenting to the emergency department: a case series. J. Emerg. Med. 2000, 18:447-451.
45. Wu J., Zou H., Strong J.A., Yu J., Zhou X., Xie Q., Zhao G., Jin M., Yu L. Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. Psychopharmacology (Berl.) 2005, 177:256-263.
46. Zawertailo L.A., Busto U.E., Tyndale R.F., Sellers E.M. Dextromethorphan's active metabolite contributes to its abuse liability. Clin. Pharmacol. Ther. 1997, 63:217-1217.